Nearly 20,000 newborns in Uganda are affected by sickle cell disease each year. Across Africa, many children with the inherited disorder die before age five because doctors diagnose it too late. Uganda has expanded mandatory newborn screening nationwide, yet gene therapy, which could potentially end years of suffering, remains out of reach for most people who need it. The gap is stark.
Late Diagnosis, Lasting Costs
“She became paralysed on the left side of her body; I just had to carry her,” said Irene Nalukwago. Her daughter was born healthy at a hospital in Kayunga, east of Kampala, but began falling sick and becoming anaemic at six months old. Her family faced repeated illness before doctors suspected a deeper problem and tests confirmed sickle cell disease.
Nalukwago’s daughter began receiving transfusions almost every week and lived with considerable pain. Now 12 years old, she has endured repeated attacks of the inherited genetic disorder. Her story puts a human cost beside the public health figure: thousands of children have gone years without early diagnosis and proper treatment.
Timing matters. The disorder causes severe pain, and medical professionals say early diagnosis helps manage it before it becomes severe. Children who need care depend on screening, treatment and continued monitoring. Late identification leaves families confronting the consequences after illness has already taken hold.
Treatment Through the Public System
Uganda has expanded mandatory newborn screening across the country, giving the state health system a central role in identifying affected children. At Kayunga Referral Hospital, medical officer Dr Isaac Tumusiime said: “All our children are started on hydroxyurea as early as nine months.” The oral prescription medication reduces painful attacks and the need for blood transfusions.
Tumusiime said the medication has a continuous supply and that adherence to treatment has been good. “Most of the children have managed to survive through this setup,” he said. The treatment marks a significant change in care, but it manages the condition rather than providing the permanent cure gene therapy could potentially offer.
Patients at the Kayunga clinic are advised to attend routine check-ups. Doctors say monitoring can detect problems early and help patients avoid life-threatening complications such as strokes. They also say regular monitoring can reduce pressure on stretched health workers and give patients a better chance of longer, healthier lives. Families must keep up with ongoing care, while clinics and medical professionals provide screening, medication and follow-up.
A Possible Cure, Still Out of Reach
Some countries have rolled out gene therapy, which could potentially end years of suffering for many patients. But Tumusiime said most people who need it can’t afford it. Hydroxyurea remains the treatment currently available in Uganda, and parents are encouraged to manage their children with the medicine while they wait for another possibility.
“with a hope that maybe one day gene therapy could be affordable,” Tumusiime said, describing what parents are encouraged to hold onto. That hope comes alongside the continuing need for early diagnosis, regular check-ups and medicine. Uganda’s expanded screening and treatment supply have helped children survive, but this account describes no self-organized community response or mutual-aid effort; clinics and medical professionals provide care, while a potential cure remains beyond the reach of most who need it.